Publications

SRT-015: Novel Therapeutic for Cholestatic Liver Diseases

Poster presentation at EASL Congress 2024 | June 5-8, 2024

SRT-015 A Second-Generation ASK1 Inhibitor for Liver Diseases Including NASH

Oral presentation at Obesity and NASH Summit 2023 | November 27-29, 2023

SRT-015 Demonstrates Preclinical Efficacy in Acute Models of Liver Injury

Poster presentation at EASL Congress 2023 | June 21-24, 2023

Development of PBPK Model to Predict Liver Exposure of SRT-015, a Next-Generation Inhibitor of ASK1

Poster presentation at EASL Congress 2023 | June 21-24, 2023

P-P38 Correlation with In Vivo Efficacy By Best-In-Class ASK1 Inhibitor SRT-015 But Not Selonsertib

Poster presentation at Keystone 2023 | March 2023

Correlation of P-P38 Modulation with Anti-Inflammatory and Anti-Fibrotic Efficacy by SRT-015

Poster presentation at NASH-TAG 2023 | January 5-7, 2023

Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of the ASK1 Inhibitor SRT-015 in Healthy Adults

Oral presentation at AASLD The Liver Meeting 2022

Anti-Inflammatory Mechanisms of ASK1 Inhibitor SRT-015

Poster presentation at AASLD The Liver Meeting 2022

Anti-fibrotic and Anti-Inflammatory Mechanisms of Best-in-Class ASK1 Inhibitor SRT-015

Poster presentation at AASLD The Liver Meeting 2020

Reduction of Hepatocyte Injury by SRT-015, a Novel Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1)

Poster presentation at AASLD The Liver Meeting 2020

SRT-015: Novel ASK1 Inhibitor for the Treatment of NASH

Poster presentation at Keystone Symposia
Integrated Pathways of Disease in NASH and NAFLD, Jan 2019